Kristina Krpina¹, Miroslav Samarzija^1,2 and Lara Baticic³*

¹Clinic for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Croatia
²Faculty of Medicine, University of Zagreb, Croatia
³Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, Croatia

*Corresponding Author: Lara Baticic, Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, Croatia.

Received: November 17, 2022; Published: January 09, 2023

Abstract

Cancer is one of the most frequently diagnosed diseases with increasing incidence worldwide. The treatment of cancer requires a multidisciplinary methodology due to the complexity of the disease, the therapeutic possibilities of personalized medicine and the peculiarities of carcinogenesis, which is essential for the selection of an appropriate therapy [1]. Extensive evidence has been published on the molecular background of cancer development and progression, which can help tailor therapy to individual patients and improve their survival prognosis. Drug-specific therapeutic methodologies for cancer have contributed to substantial enhancements in overall survival and general quality of life for patients. However, there remains a pronounced need to expand personalization of treatments based on genetic and epigenetic tumor profiles in order to maximize quality and efficiency while limiting cytotoxicity of the oncological treatment. Early detection, accurate diagnosis, and treatment monitoring of cancer with specific markers and targeted molecular testing can be of great benefit to cancer patients [2].

References

1. Nussinov R., et al. “Anticancer drug resistance: An update and perspective”. Drug Resistance Updates 59 (2021): 100796.
2. Doran CG and Pennington SR. “Copy number alteration signatures as biomarkers in cancer: a review”. Biomark Medicine5 (2022): 371-386.
3. Ray A and Vohra TK. “Liquid biopsy—from bench to bedside”. Neurooncology Advances2 (2022): ii66-72.
4. Verbanac D., et al. “Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy”. International Journal of Molecular Sciences 9 (2021): 4327.
5. Domínguez-Vigil IG., et al. “The dawn of the liquid biopsy in the fight against cancer”. Oncotarget 2 (2017): 2912-2922.
6. Sholl LM., et al. “Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy”. Cancer Research16 (2016): 3197-3199.
7. Ai L., et al. “Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond”. Advances in Experimental Medicine and Biology 1248 (2020): 33-59.
8. Mezquita L., et al. “Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer”. JAMA Oncology3 (2018): 351-357.
9. Pezeshki PS and Rezaei N. “Immune checkpoint inhibition in COVID-19: risks and benefits”. Expert Opinion on Biological Therapy 9 (2021): 1173-1179.
10. Krpina K., et al. “Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection”. Journal of Clinical Medicine 11 (2022): 6695.

Citation

Citation: Lara Baticic., et al. “New Biomarkers in Oncology in the COVID-19 Era”.Acta Scientific Medical Sciences 7.2 (2023): 44-46.

Copyright

Copyright: © 2022 Lara Baticic., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.